PEGylated dendritic diaminocyclohexyl-platinum (II) conjugates aspH-responsive drug delivery vehicles with enhanced tumor accumulation and antitumor efficacy

Biomaterials

Volumn 35, Issue 38, 2014, Pages 10080-10092

  Pan, Dayi ^a   she, Wenchuan ^a   Guo, Chunhua ^a   Luo, Kui ^a   Yi, Qiangying ^a   Gu, Zhongwei ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Biodistribution; Drug delivery system; Ovarian cancer; Oxaliplatin; Peptide dendrimer; PH responsive

Indexed keywords

CONTROLLED DRUG DELIVERY; DENDRIMERS; DISEASES; DRUG PRODUCTS; MAMMALS; ONCOLOGY; PEPTIDES; TARGETED DRUG DELIVERY; TUMORS;

BIODISTRIBUTIONS; DRUG DELIVERY SYSTEM; OVARIAN CANCERS; OXALIPLATIN; PEPTIDE DENDRIMERS; PH-RESPONSIVE;

PLATINUM COMPOUNDS;

DENDRIMER; DIAMINOCYCLOHEXYLPLATINUM DERIVATIVE; OXALIPLATIN; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG; 1,2-DIAMINOCYCLOHEXYL PLATINUM SULFATE; ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; NANOCAPSULE; NANOCONJUGATE; PLATINUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DENDRITE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IC50; MOUSE; NONHUMAN; OVARY CANCER; PH; ANIMAL; APOPTOSIS; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DRUG EFFECTS; METABOLIC CLEARANCE RATE; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; METABOLIC CLEARANCE RATE; NANOCAPSULES; NANOCONJUGATES; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 84908101844     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.09.006     Document Type: Article

References (62)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
2. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307-320.
3. Graham M.A., Lockwood G.F., Greenslade D., Brienza S., Bayssas M., Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000, 6:1205-1218.
4. Dou Y.N., Zheng J., Foltz W.D., Weersink R., Chaudary N., Jaffray D.A., et al. Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice. JControl Release 2014, 178:69-78.
5. Zhou D., Xiao H., Meng F., Li X., Li Y., Jing X., et al. APolymer-(Tandem drugs) conjugate for enhanced Cancer treatment. Adv Healthc Mater 2013, 2:822-827.
6. Chen G., Kumar J., Gregory A., Stenzel M.H. Efficient synthesis of dendrimers via a thiol-yne and esterification process and their potential application in the delivery of platinum anti-cancer drugs. Chem Commun 2009, 6291-6293.
7. Song W., Tang Z., Zhang D., Zhang Y., Yu H., Li M., et al. Anti-tumor efficacy of c(RGDfK)-decorated polypeptide-based micelles co-loaded with docetaxel and cisplatin. Biomaterials 2014, 35:3005-3014.
8. Wang Y., Zhou J., Qiu L., Wang X., Chen L., Liu T., et al. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells. Biomaterials 2014, 35:4297-4309.
9. Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. JControl Release 2012, 164:138-144.
10. Li M., Tang Z., Lv S., Song W., Hong H., Jing X., et al. Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin. Biomaterials 2014, 35:3851-3864.
11. Davis M.E., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7:771-782.
12. Ke C.-J., Chiang W.-L., Liao Z.-X., Chen H.-L., Lai P.-S., Sun J.-S., et al. Real-time visualization of pH-responsive PLGA hollow particles containing a gas-generating agent targeted for acidic organelles for overcoming multi-drug resistance. Biomaterials 2013, 34:1-10.
13. Xiao H., Noble G.T., Stefanick J.F., Qi R., Kiziltepe T., Jing X., et al. Photosensitive Pt (IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy invivo. JControl Release 2014, 173:11-17.
14. Kaneshiro T.L., Lu Z.-R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 2009, 30:5660-5666.
15. Burger K.N., Staffhorst R.W., de Vijlder H.C., Velinova M.J., Bomans P.H., Frederik P.M., et al. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat Med 2002, 8:81-84.
16. Newman M.S., Colbern G.T., Working P.K., Engbers C., Amantea M.A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemoth Pharm 1999, 43:1-7.
17. Ye H., Jin L., Hu R., Yi Z., Li J., Wu Y., et al. Poly (γ, l-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 2006, 27:5958-5965.
18. Brown S.D., Nativo P., Smith J.-A., Stirling D., Edwards P.R., Venugopal B., et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. JAm Chem Soc 2010, 132:4678-4684.
19. Cabral H., Nishiyama N., Kataoka K. Optimization of (1,2-diamino-cyclohexane) platinum (II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. JControl Release 2007, 121:146-155.
20. Cabral H., Nishiyama N., Okazaki S., Koyama H., Kataoka K. Preparation and biological properties of dichloro (1, 2-diaminocyclohexane) platinum(II) (DACHPt)-loaded polymeric micelles. JControl Release 2005, 101:223-232.
21. Rice J.R., Gerberich J.L., Nowotnik D.P., Howell S.B. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 2006, 12:2248-2254.
22. Campone M., Rademaker-Lakhai J.M., Bennouna J., Howell S.B., Nowotnik D.P., Beijnen J.H., et al. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemoth Pharm 2007, 60:523-533.
23. Nowotnik D.P., Cvitkovic E. ProLindac™(AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv Drug Deliv Rev 2009, 61:1214-1219.
24. Duangjai A., Luo K., Zhou Y., Yang J., Kopeček J. Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells. Eur J Pharm Biopharm 2014, 87:187-196.
25. Sood P., Thurmond K.B., Jacob J.E., Waller L.K., Silva G.O., Stewart D.R., et al. Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. Bioconjugate Chem 2006, 17:1270-1279.
26. Fox M.E., Szoka F.C., Fréchet J.M. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Accounts Chem Res 2009, 42:1141-1151.
27. Chen B., Jerger K., Fréchet J.M., Szoka F.C. The influence of polymer topology on pharmacokinetics: differences between cyclic and linear PEGylated poly (acrylic acid) comb polymers. JControl Release 2009, 140:203-209.
28. Pan H., Sima M., Yang J., Kopeček J. Synthesis of long-circulating, backbone degradable HPMA Copolymer-Doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy. Macromol Biosci 2013, 13:155-160.
29. Luo K., He B., Wu Y., Shen Y., Gu Z. Functional and biodegradable dendritic macromolecules as efficient and nontoxic gene vectors. Biotechnol Adv 2014, 32:818-830.
30. Lee C.C., MacKay J.A., Fréchet J.M., Szoka F.C. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23:1517-1526.
31. Luo K., Li C., Wang G., Nie Y., He B., Wu Y., et al. Peptide dendrimers as efficient and biocompatible gene delivery vectors: synthesis and invitro characterization. JControl Release 2011, 155:77-87.
32. Luo K., Li C., Li L., She W., Wang G., Gu Z. Arginine functionalized peptide dendrimers as potential gene delivery vehicles. Biomaterials 2012, 33:4917-4927.
33. Zhu S., Hong M., Tang G., Qian L., Lin J., Jiang Y., et al. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31:1360-1371.
34. Luo K., Liu G., She W., Wang Q., Wang G., He B., et al. Gadolinium-labeled peptide dendrimers with controlled structures as potential magnetic resonance imaging contrast agents. Biomaterials 2011, 32:7951-7960.
35. Yellepeddi V.K., Kumar A., Maher D.M., Chauhan S.C., Vangara K.K., Palakurthi S. Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT. Anticancer Res 2011, 31:897-906.
36. Haririan I., Alavidjeh M.S., Khorramizadeh M.R., Ardestani M.S., Ghane Z.Z., Namazi H. Anionic linear-globular dendrimer-cis-platinum (II) conjugates promote cytotoxicity invitro against different cancer cell lines. Int J Nanomed 2010, 5:63.
37. Kapp T., Dullin A., Gust R. Platinum (II)- dendrimer conjugates: synthesis and investigations on cytotoxicity, cellular distribution, platinum release, DNA, and protein binding. Bioconjugate Chem 2010, 21:328-337.
38. Aronov O., Horowitz A.T., Gabizon A., Gibson D. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and invitro studies. Bioconjugate Chem 2003, 14:563-574.
39. Zhu X.D., Zhang J.B., Zhuang P.Y., Zhu H.G., Zhang W., Xiong Y.Q., et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. JClin Oncol 2008, 26:2707-2716.
40. Hu-Lowe D.D., Zou H.Y., Grazzini M.L., Hallin M.E., Wickman G.R., Amundson K., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008, 14:7272-7283.
41. Jallal H., Valentino M.-L., Chen G., Boschelli F., Ali S., Rabbani S.A. ASrc/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis invitro and invivo. Cancer Res 2007, 67:1580-1588.
42. Tekade R.K., Kumar P.V., Jain N.K. Dendrimers in oncology: an expanding horizon. Chem Rev 2008, 109:49-87.
43. Astruc D., Boisselier E., Ornelas C. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics, and nanomedicine. Chem Rev 2010, 110:1857-1959.
44. She W., Luo K., Zhang C., Wang G., Geng Y., Li L., et al. The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy. Biomaterials 2013, 34:1613-1623.
45. Polyethylene glycol [MAK Value Documentation, 1998] 2002, MAK-Collection Occup Health Saf Wiley-VCH Verlag GmbH Co KGaA.
46. Zhang Y., Xiao C., Li M., Ding J., He C., Zhuang X., et al. Core-cross-linked micellar nanoparticles from a linear-dendritic prodrug for dual-responsive drug delivery. Polym Chem 2014, 5:2801-2808.
47. Li M., Tang Z., Sun H., Ding J., Song W., Chen X. pH and reduction dual-responsive nanogel cross-linked by quaternization reaction for enhanced cellular internalization and intracellular drug delivery. Polym Chem 2013, 4:1199-1207.
48. Mura S., Nicolas J., Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater 2013, 12:991-1003.
49. Schmaljohann D. Thermo-and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev 2006, 58:1655-1670.
50. Furin A., Guiotto A., Baccichetti F., Pasut G., Deuschel C., Bertani R., et al. Synthesis, characterization and preliminary cytotoxicity assays of poly (ethylene glycol)-malonato-Pt-DACH conjugates. Eur J Med Chem 2003, 38:739-749.
51. Soo Sohn Y., Baek H., Ha Cho Y., Lee Y.-A., Jung O.-S., Ok Lee C., et al. Synthesis and antitumor activity of novel polyphosphazene-(diamine) platinum (II) conjugates. Int J Pharm 1997, 153:79-91.
52. Aggarwal P., Hall J.B., McLeland C.B., Dobrovolskaia M.A., McNeil S.E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 2009, 61:428-437.
53. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
54. Barreto J.A., O'Malley W., Kubeil M., Graham B., Stephan H., Spiccia L. Nanomaterials: applications in Cancer imaging and therapy. Adv Mater 2011, 23:H18-H40.
55. Li N., Li N., Yi Q.Y., Luo K., Guo C.H., Pan D.Y., et al. Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent. Biomaterials 2014, 35:29-45.
56. Zhang C.Y., Pan D.Y., Luo K., Li N., Guo C.H., Zheng X.L., et al. Dendrimer-doxorubicin conjugate as enzyme-sensitive and polymeric nanoscale drug delivery vehicle for ovarian cancer therapy. Polym Chem 2014, 5:5227-5235.
57. Zhang C.Y., Pan D.Y., Luo K., She W.C., Guo C.H., Yang Y., et al. Peptide dendrimer-doxorubicin conjugate based nanoparticle as enzyme-responsive drug delivery system for cancer therapy. Adv Healthc Mater 2014, 3:1299-1308.
58. Nel A., Xia T., Mädler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
59. Sharifi S., Behzadi S., Laurent S., Forrest M.L., Stroeve P., Mahmoudi M. Toxicity of nanomaterials. Chem Soc Rev 2012, 41:2323-2343.
60. Aillon K.L., Xie Y., El-Gendy N., Berkland C.J., Forrest M.L. Effects of nanomaterial physicochemical properties on invivo toxicity. Adv Drug Deliv Rev 2009, 61:457-466.
61. Crespo L., Sanclimens G., Pons M., Giralt E., Royo M., Albericio F. Peptide and amide bond-containing dendrimers. Chem Rev 2005, 105:1663-1682.
62. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003, 2:214-221.